- Study found people who get the Pfizer vaccine are 94% less likely to develop symptomatic COVID-19.
- Israeli researchers found that fully vaccinated people are 92% less likely to develop severe cases.
- The study compared 600,000 vaccinated people to same size group of unvaccinated people, Reuters wrote.
People who get the Pfizer-BioNTech coronavirus vaccine are far less likely to develop symptomatic or severe COVID-19, according to a new study out of Israel.
Researchers from Israel’s largest healthcare provider, Clalit, looked at 600,000 Israelis who had received two doses of the Pfizer shot.
They reported a 94% drop in symptomatic coronavirus infections — when patients develop symptoms like fever or shortness of breath — among people who had been vaccinated compared to those who had not, Reuters reported Sunday.
The preliminary study, which has not yet been peer-reviewed, also found that people who had been fully vaccinated were 92% less likely to develop severe COVID-19 that may require hospitalisation, intensive care, or a ventilator.
In December, Pfizer reported its vaccine was 95% effective at preventing symptomatic coronavirus infections during clinical trials. The new Clalit study underscores that effectiveness among the general public outside of a controlled trial setting.
“It shows unequivocally that Pfizer’s coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it was found to be in the clinical study,” Ran Balicer, Clalit’s chief innovation officer, told Reuters.
Read the article by Aylin Woodward in Business Insider Australia.